OCEA Ocean Biomedical, Inc.
Pharmaceutical Preparations · OTC · SEC CIK 1869974 · Fiscal year ends 12/31
Financial factors as of 2025-03-31 (2025Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY1.6%
TTM EPS YoY6.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-1,276.3%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets5,940.6%
Debt / equity—
Current ratio0.06x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.14x
Accruals ratio-1,097.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2025Q12025-03-31 | 2024Q4*2024-12-31 | 2024Q32024-09-30 | 2024Q22024-06-30 | 2024Q12024-03-31 | 2023Q4*2023-12-31 | 2023Q32023-09-30 | 2023Q22023-06-30 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $18,000 | $0 | $0 | $0 | $26,000 | -$17,000 | $305,000 | $28,000 |
| SG&A expense | $940,000 | $1.75M | $768,000 | $682,000 | $569,000 | -$643,000 | $2.35M | $2.80M |
| Operating income | -$958,000 | -$1.75M | -$768,000 | -$682,000 | -$595,000 | $660,000 | -$2.65M | -$2.83M |
| Interest expense | $343,000 | — | — | -$337,000 | $637,000 | $13,148 | $0 | $24,046 |
| Net income | -$8.24M | $283,000 | -$3.70M | -$17.23M | $13.00M | -$16.86M | -$14.09M | -$11.43M |
| EPS (basic) | -0.09 | — | -0.13 | -0.63 | 0.48 | — | -0.53 | -0.43 |
| EPS (diluted) | -0.09 | — | -0.13 | -0.63 | 0.48 | — | -0.53 | -0.43 |
| Weighted avg. shares (diluted) | 91.02M | — | 27.49M | 27.49M | 27.34M | — | 26.61M | 26.47M |
| Banking | ||||||||
| Net interest income | — | -$433,000 | -$461,000 | -$515,000 | -$637,000 | -$500,000 | -$293,000 | -$668,000 |
| Balance sheet | ||||||||
| Cash & equivalents | $800,000 | $200,000 | $200,000 | $200,000 | $19,000 | $4,000 | $1.00M | $1.10M |
| Current assets | $1.49M | $812,000 | $1.04M | $1.28M | $1.80M | $2.11M | $1.03M | $2.16M |
| Total assets | $1.58M | $902,000 | $1.13M | $1.85M | $2.95M | $5.50M | $1.03M | $2.16M |
| Current liabilities | $26.57M | $33.89M | $31.82M | $30.74M | $30.11M | $30.01M | $30.85M | $29.79M |
| Short-term debt | — | — | — | — | — | $3.20M | — | $11.87M |
| Total liabilities | $93.98M | $98.52M | $97.39M | $94.59M | $78.73M | $96.26M | $76.25M | $63.82M |
| Shareholders' equity | -$92.40M | -$97.62M | -$96.26M | -$92.74M | -$75.78M | -$90.76M | -$75.22M | -$61.66M |
| Shares outstanding | 166.01M | 34.87M | 34.87M | 34.87M | 34.82M | 34.65M | 34.09M | 34.01M |
| Cash flow statement | ||||||||
| Operating cash flow | -$356,000 | -$2.52M | -$885,000 | -$290,000 | -$485,000 | -$866,000 | -$1.13M | -$4.78M |
| Financing cash flow | $909,000 | $2.50M | — | — | — | $839,000 | $0 | $6.64M |
| Stock-based compensation | $186,000 | $186,000 | $186,000 | $187,000 | $186,000 | $187,000 | $186,000 | $186,000 |
Free plan shows the latest 8 periods; Pro shows all 15 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.